Dynamics of Chronic Myeloid Leukemia Under Imatinib Treatment: A Study of Resistance Development

被引：0
作者：
Badralexi, Irina [1 ]
Bordei, Ana-Maria [2 ]
Halanay, Andrei [3 ]
Radulescu, Ileana Rodica [1 ]
机构：
[1] Natl Univ Sci & Technol, Politehn Bucharest, Dept Math Methods & Models, Bucharest 060042, Romania
[2] Natl Inst Aerosp Res Elie Carafoli INCAS Bucharest, Bucharest 061126, Romania
[3] Natl Univ Sci & Technol, Politehn Bucharest, Dept Math & Informat, Bucharest 060042, Romania
来源：
MATHEMATICS | 2024年 / 12卷 / 24期
关键词：
chronic myeloid leukemia; asymmetric division; immune system; imatinib; delay differential equations; MATHEMATICAL-MODEL; DELAY SYSTEMS; STABILITY; HEMATOPOIESIS; BIOLOGY; CELLS;
D O I：
10.3390/math12243937
中图分类号：
O1 [数学];
学科分类号：
0701 ; 070101 ;
摘要：
Chronic myeloid leukemia (CML) is a hematological disorder characterized by the abnormal proliferation of leukemic cells. This study aims to model the dynamics of leukemic and healthy cell populations in CML, considering the role of the immune system and the effects of treatment with Imatinib. The model also addresses the development of treatment resistance in cells, following the Goldie-Coldman hypothesis. We employ a system of delay differential equations to simulate the interactions between leukemic cells, healthy cells, and the immune system under treatment. The results provide insights into the dynamic balance between leukemic cells, healthy cells, and immune responses, and the impact of developing resistance on treatment outcomes.
引用
收藏
页数：17
相关论文
共 50 条
  • [31] INFLUENCE OF TREATMENT WITH IMATINIB ON PURINERGIC SIGNALING IN CHRONIC MYELOID LEUKEMIA CELLS.
    Willig, J. B.
    Vianna, D. R. B.
    Beckenkamp, A.
    Beckenkamp, L. R.
    Gnoatto, S. C. B.
    Wink, M. R.
    Pilger, D. A.
    PURINERGIC SIGNALLING, 2018, 14 : S99 - S99
  • [32] Assessment of Imatinib in the treatment of chronic myeloid leukemia in Gabon: a cohort of 17 cases
    Mbethe, Gaudong G. L.
    Mounguengui, D., I
    Magne, C.
    Ondounda, M.
    Yboutsi, L.
    Ibaba, J.
    Kombila, Moussavou J. B.
    Boguikouma, J. B.
    Belembaogo, E.
    Nzenze, J. R.
    MEDECINE ET SANTE TROPICALES, 2016, 26 (02): : 184 - 188
  • [33] Changes in bone metabolic parameters in children with chronic myeloid leukemia on imatinib treatment
    Jaeger, Bernadette Anna Sophia
    Tauer, Josephine Tabea
    Ulmer, Anna
    Kuhlisch, Eberhard
    Roth, Heinz Juergen
    Suttorp, Meinolf
    MEDICAL SCIENCE MONITOR, 2012, 18 (12): : CR721 - CR728
  • [34] Comparison of the Efficacy of Nilotinib and Imatinib in the Treatment of Chronic Myeloid Leukemia
    Zhang, Bang-Shuo
    Chen, Yong-Ping
    Lv, Jing-Long
    Yang, Yi
    JCPSP-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN, 2019, 29 (07): : 631 - 634
  • [35] Treatment with dasatinib for chronic myeloid leukemia following imatinib-induced hepatotoxicity
    Harbaum, Lars
    Marx, Andreas
    Goekkurt, Eray
    Schafhausen, Philippe
    Atanackovic, Djordje
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2014, 99 (01) : 91 - 94
  • [36] Imatinib in Very Elderly Patients with Chronic Myeloid Leukemia in Chronic Phase: A Retrospective Study
    Roberto Latagliata
    Dario Ferrero
    Alessandra Iurlo
    Francesco Cavazzini
    Fausto Castagnetti
    Elisabetta Abruzzese
    Carmen Fava
    Massimo Breccia
    Mario Annunziata
    Fabio Stagno
    Mario Tiribelli
    Gianni Binotto
    Giovanna Mansueto
    Antonella Gozzini
    Sabina Russo
    Laura Cavalli
    Enrico Montefusco
    Gabriele Gugliotta
    Michele Cedrone
    Antonella Russo Rossi
    Paolo Avanzini
    Patrizia Pregno
    Endri Mauro
    Antonio Spadea
    Francesca Celesti
    Gianfranco Giglio
    Alessandro Isidori
    Monica Crugnola
    Elisabetta Calistri
    Federica Sorà
    Stefano Storti
    Ada D’Addosio
    Giovanna Rege-Cambrin
    Luigiana Luciano
    Giuliana Alimena
    Drugs & Aging, 2013, 30 : 629 - 637
  • [37] Use of deferasirox, an iron chelator, to overcome imatinib resistance of chronic myeloid leukemia cells
    Kim, Dae Sik
    Na, Yoo Jin
    Kang, Myoung Hee
    Yoon, Soo-Young
    Choi, Chul Won
    KOREAN JOURNAL OF INTERNAL MEDICINE, 2016, 31 (02) : 357 - 366
  • [38] Population Pharmacokinetics of Imatinib in Nigerians With Chronic Myeloid Leukemia: Clinical Implications for Dosing and Resistance
    Adeagbo, Babatunde Ayodeji
    Olugbade, Tiwalade Adewale
    Durosinmi, Muheez Alani
    Bolarinwa, Rahman Ayodele
    Ogungbenro, Kayode
    Bolaji, Oluseye Oladotun
    JOURNAL OF CLINICAL PHARMACOLOGY, 2017, 57 (12) : 1554 - 1563
  • [39] Relationship between Oxidative Stress and Imatinib Resistance in Model Chronic Myeloid Leukemia Cells
    Glowacki, Sylwester
    Synowiec, Ewelina
    Szwed, Marzena
    Toma, Monika
    Skorski, Tomasz
    Sliwinski, Tomasz
    BIOMOLECULES, 2021, 11 (04)
  • [40] Pharmaceutical inhibition of BCL6 ameliorates resistance to imatinib in chronic myeloid leukemia
    Xiao, Yingying
    Deng, Fang
    Luo, Yun
    Wang, Teng
    HELIYON, 2024, 10 (16)
12345